Skin diagnostics company DermTech files for a $25 million IPO

By Renaissance Capital,

Shutterstock photo

DermTech, which is developing non-invasive gene expression tests to diagnosis various skin conditions, filed on Friday with the SEC to raise up to $25 million in an initial public offering. The La Jolla, CA-based company, which was founded in 1995, plans to list on the NASDAQ under the symbol DMTK. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by